| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to see the in vivo function of genetic mutations that are related to the epigenetic alterations in acute myeloid leukemia (AML). We focused on the DNMT3A R882H mutation among them. Human CD34+ cells transduced with DNMT3A R882H reduced the expression of myelomonocytic markers such as CD14 and the formation of CFU-mix and CFU-GM in the colony formation assays. However, these cells could not develop AML in NOG mice when they were transplanted. Taken together, these findings suggest that the transduction of DNMT3A R882H was not enough for the development of AML in vivo.
|
